A randomized, double-blind, placebo-controlled study assessing the effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes
Latest Information Update: 26 Aug 2021
At a glance
- Drugs Mecasermin rinfabate (Primary)
- Indications Lung disorders
- Focus Pharmacodynamics
- 26 Aug 2021 New trial record